Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

dc.contributor.authorSwisher, Elizabeth M
dc.contributor.authorLin, Kevin K
dc.contributor.authorOza, Amit M
dc.contributor.authorScott, Clare L
dc.contributor.authorGiordano, Heidi
dc.contributor.authorSun, James
dc.contributor.authorKonecny, Gottfried E
dc.contributor.authorColeman, Robert L
dc.contributor.authorTinker, Anna V
dc.contributor.authorO'Malley, David M
dc.contributor.authorKristeleit, Rebecca S
dc.contributor.authorMa, Ling
dc.contributor.authorBell-McGuinn, Katherine M
dc.contributor.authorBrenton, James D
dc.contributor.authorCragun, Janiel M
dc.contributor.authorOaknin, Ana
dc.contributor.authorRay-Coquard, Isabelle
dc.contributor.authorHarrell, Maria I
dc.contributor.authorMann, Elaina
dc.contributor.authorKaufmann, Scott H
dc.contributor.authorFloquet, Anne
dc.contributor.authorLeary, Alexandra
dc.contributor.authorHarding, Thomas C
dc.contributor.authorGoble, Sandra
dc.contributor.authorMaloney, Lara
dc.contributor.authorIsaacson, Jeff
dc.contributor.authorAllen, Andrew R
dc.contributor.authorRolfe, Lindsey
dc.contributor.authorYelensky, Roman
dc.contributor.authorRaponi, Mitch
dc.contributor.authorMcNeish, Iain A
dc.contributor.orcidBrenton, James [0000-0002-5738-6683]
dc.description.abstractBACKGROUND: Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1 and BRCA2 (BRCA) mutations genomic loss of heterozygosity (LOH) might also represent homologous recombination deficiency. In ARIEL2, we assessed the ability of tumour genomic LOH, quantified with a next-generation sequencing assay, to predict response to rucaparib, an oral PARP inhibitor. METHODS: ARIEL2 is an international, multicentre, two-part, phase 2, open-label study done at 49 hospitals and cancer centres in Australia, Canada, France, Spain, the UK, and the USA. In ARIEL2 Part 1, patients with recurrent, platinum-sensitive, high-grade ovarian carcinoma were classified into one of three predefined homologous recombination deficiency subgroups on the basis of tumour mutational analysis: BRCA mutant (deleterious germline or somatic), BRCA wild-type and LOH high (LOH high group), or BRCA wild-type and LOH low (LOH low group). We prespecified a cutoff of 14% or more genomic LOH for LOH high. Patients began treatment with oral rucaparib at 600 mg twice per day for continuous 28 day cycles until disease progression or any other reason for discontinuation. The primary endpoint was progression-free survival. All patients treated with at least one dose of rucaparib were included in the safety analyses and all treated patients who were classified were included in the primary endpoint analysis. This trial is registered with, number NCT01891344. Enrolment into ARIEL2 Part 1 is complete, although an extension (Part 2) is ongoing. FINDINGS: 256 patients were screened and 206 were enrolled between Oct 30, 2013, and Dec 19, 2014. At the data cutoff date (Jan 18, 2016), 204 patients had received rucaparib, with 28 patients remaining in the study. 192 patients could be classified into one of the three predefined homologous recombination deficiency subgroups: BRCA mutant (n=40), LOH high (n=82), or LOH low (n=70). Tumours from 12 patients were established as BRCA wild-type, but could not be classified for LOH, because of insufficient neoplastic nuclei in the sample. The median duration of treatment for the 204 patients was 5·7 months (IQR 2·8-10·1). 24 patients in the BRCA mutant subgroup, 56 patients in the LOH high subgroup, and 59 patients in the LOH low subgroup had disease progression or died. Median progression-free survival after rucaparib treatment was 12·8 months (95% CI 9·0-14·7) in the BRCA mutant subgroup, 5·7 months (5·3-7·6) in the LOH high subgroup, and 5·2 months (3·6-5·5) in the LOH low subgroup. Progression-free survival was significantly longer in the BRCA mutant (hazard ratio 0·27, 95% CI 0·16-0·44, p<0·0001) and LOH high (0·62, 0·42-0·90, p=0·011) subgroups compared with the LOH low subgroup. The most common grade 3 or worse treatment-emergent adverse events were anaemia or decreased haemoglobin (45 [22%] patients), and elevations in alanine aminotransferase or aspartate aminotransferase (25 [12%]). Common serious adverse events included small intestinal obstruction (10 [5%] of 204 patients), malignant neoplasm progression (10 [5%]), and anaemia (nine [4%]). Three patients died during the study (two because of disease progression and one because of sepsis and disease progression). No treatment-related deaths occurred. INTERPRETATION: In patients with BRCA mutant or BRCA wild-type and LOH high platinum-sensitive ovarian carcinomas treated with rucaparib, progression-free survival was longer than in patients with BRCA wild-type LOH low carcinomas. Our results suggest that assessment of tumour LOH can be used to identify patients with BRCA wild-type platinum-sensitive ovarian cancers who might benefit from rucaparib. These results extend the potential usefulness of PARP inhibitors in the treatment setting beyond BRCA mutant tumours. FUNDING: Clovis Oncology, US Department of Defense Ovarian Cancer Research Program, Stand Up To Cancer-Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant, and V Foundation Translational Award.
dc.publisherElsevier BV
dc.subjectAntineoplastic Agents
dc.subjectBRCA1 Protein
dc.subjectBRCA2 Protein
dc.subjectCarcinoma, Ovarian Epithelial
dc.subjectDrug Resistance, Neoplasm
dc.subjectFallopian Tube Neoplasms
dc.subjectFollow-Up Studies
dc.subjectGerm-Line Mutation
dc.subjectInternational Agencies
dc.subjectMiddle Aged
dc.subjectNeoplasm Recurrence, Local
dc.subjectNeoplasm Staging
dc.subjectNeoplasms, Glandular and Epithelial
dc.subjectOvarian Neoplasms
dc.subjectPeritoneal Neoplasms
dc.subjectPoly(ADP-ribose) Polymerase Inhibitors
dc.subjectPoly(ADP-ribose) Polymerases
dc.subjectProspective Studies
dc.subjectSalvage Therapy
dc.subjectSurvival Rate
dc.titleRucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
prism.publicationNameLancet Oncol
rioxxterms.typeJournal Article/Review
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
_ARIEL2_HRD_LO Collated Sub_accepted.pdf
1.8 MB
Adobe Portable Document Format
Accepted version
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
417.78 KB
Adobe Portable Document Format